Odyssey Therapeutics Inc.

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.